Karyopharm Therapeutics’ (KPTI) “Overweight” Rating Reiterated at Piper Sandler

Piper Sandler reaffirmed their overweight rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a research report sent to investors on Thursday,Benzinga reports. They currently have a $12.00 price target on the stock, down from their prior price target of $15.00.

A number of other equities research analysts have also issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Karyopharm Therapeutics in a research report on Wednesday. HC Wainwright downgraded Karyopharm Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, July 16th. Finally, Robert W. Baird lowered their price target on Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Karyopharm Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $20.60.

Karyopharm Therapeutics Stock Down 5.5%

Shares of Karyopharm Therapeutics stock opened at $5.50 on Thursday. The stock’s fifty day moving average is $6.00 and its 200-day moving average is $5.16. The firm has a market capitalization of $47.69 million, a PE ratio of -0.38 and a beta of 0.34. Karyopharm Therapeutics has a 12-month low of $3.51 and a 12-month high of $16.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Monday, August 11th. The company reported ($4.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.80) by ($0.52). The firm had revenue of $37.93 million during the quarter, compared to the consensus estimate of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. Analysts expect that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of KPTI. Baird Financial Group Inc. purchased a new position in Karyopharm Therapeutics in the second quarter valued at about $45,000. XTX Topco Ltd purchased a new position in Karyopharm Therapeutics in the second quarter valued at about $56,000. Two Sigma Investments LP grew its stake in Karyopharm Therapeutics by 60.3% in the fourth quarter. Two Sigma Investments LP now owns 137,786 shares of the company’s stock valued at $93,000 after purchasing an additional 51,856 shares in the last quarter. Bridgeway Capital Management LLC purchased a new position in Karyopharm Therapeutics in the second quarter valued at about $163,000. Finally, Silverback Asset Management LLC grew its stake in Karyopharm Therapeutics by 40.0% in the second quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock valued at $302,000 after purchasing an additional 20,000 shares in the last quarter. Hedge funds and other institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).